Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
INDICATE
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT04423211 ↗
- Recruiting
- ECOG-ACRIN Cancer Research Group
- Focused
We haven't built an HCP commentary report on INDICATE yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on INDICATE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy; Apalutamide; Computed Tomography; Degarelix; External Beam Radiation Therapy; Fluciclovine F18; Goserelin Acetate; Intensity-Modulated Proton Therapy; Intensity-Modulated Radiation Therapy; Leuprolide Acetate; Magnetic Resonance Imaging; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Relugolix; Stereotactic Body Radiation Therapy; Triptorelin; Volume Modulated Arc Therapy
- Arms
- Arm A (EBRT, short-term androgen deprivation therapy [STAD]) · Active comparator
- Arm B (EBRT, STAD, apalutamide) · Experimental
- Arm C (EBRT, STAD, apalutamide) · Experimental
- Arm D (EBRT, STAD, apalutamide, RT) · Experimental
- Enrollment
- 804 (estimated)
- Primary outcomes
- Progression-free survival (PFS)
- PFS prolongation in patients without PET-evidence of extrapelvic metastases
- PFS prolongation in patients with PET-evidence of extrapelvic metastases
- Quality of life (QOL)
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Oct 8, 2020
- Primary completion
- Dec 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT04423211 · updated Aug 19, 2026
Publications
linked from the registry- Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, Chou R, Jacene HA, Kamran SC, Kim SK, Kirkby E, Luckenbaugh AN, Nathanson BJ, Nyame YA, Posadas EM, Tran PT, Chen RC. Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024 Apr;211(4):518-525. doi: 10.1097/JU.0000000000003891. Epub 2024 Feb 29. PubMed 38421243